| ABBVIE INC. DL-,01 |
| USA |
| Gesundheit |
| US00287Y1091 / A1J84E |
| 4AB (Frankfurt) / ABBV (NYSE) |
| FRA:4AB, ETR:4AB, 4AB:GR, NYSE:ABBV |
| S&P500 |
| https://www.abbvie.com/ |
|
AbbVie Inc. is a research-based biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative medicines and therapies worldwide. The company maintains a strong focus on immunology, offering treatments like Humira, Sk..
>Volltext.. |
| 402126.64 Mio. EUR |
| 457001.87 Mio. EUR |
| 55127.11 Mio. EUR |
| 25618.46 Mio. EUR |
| 3154.81 Mio. EUR |
| 1.78 EUR |
| 63936.89 Mio. EUR |
| 8241.12 Mio. EUR |
| 18625.22 Mio. EUR |
| 0.22 |
| 2.54% |
| -18.98% |
| 5.88 EUR |
| 2.6% |
| 2.67% |
| 15.07.26 - 1.5115011€ 15.04.26 - 1.467559€ >weitere anzeigen... |
| - |
| ABBVIE |
| 28.07.26 |
|
||||
|